This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n15http://localhost/temp/predkladatel/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n18http://bibframe.org/vocab/
n17http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11150%2F14%3A10271899%21RIV15-MSM-11150___/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11150%2F14%3A10271899%21RIV15-MSM-11150___
rdf:type
skos:Concept n11:Vysledek
rdfs:seeAlso
http://dx.doi.org/10.7785/tcrt.2012.500352
dcterms:description
To quantitatively evaluate the extent to which fiducial-based image-guidance improves dose coverage of the target volume and sparing of critical organs for prostate cancer patients treated with intensity modulated radiotherapy (IMRT) and determination of planning margins by original approach of detailed daily dose volume histogram (DVH) and patient's position correction analysis. Sixty-two patients divided in two groups (clinical target volume (CTV) -> planning target volume (PTV) margin 10 and 7 mm) were treated with IMRT using implanted fiducial markers. Each patient's treatment fraction was recalculated as it would have been treated without fiducial-guided positioning. For both plans (IGRT and non-IGRT), equivalent uniform doses (EUD), maximal and minimal doses for target volumes, normal tissue complication probability (NTCP), maximum and mean doses for organs at risk and the whole DVH differences were assessed. In the group with 10 mm margins, the only significant difference was worse rectal NTCP by 4.5%, but the CTV dose coverage remained at the same level. Recalculated plans with 7 mm margin could not achieve the prescribed target volume coverage, and the EUD decreased by 3.7 and 0.6 Gy for PTV and CTV, respectively. Desired CTV -> PTV margin for non-IGRT plans should be no lower than 12 mm to guarantee 95% instances when delivered dose to CTV maintain as planned, for IGRT plans decrease this requirement to 2mm. Prostate IMRT strategies involving margin reduction below 7 mm require image-guidance to maintain the planned dose coverage. Using fiducial-based image-guidance and large margins seems to be superfluous. To quantitatively evaluate the extent to which fiducial-based image-guidance improves dose coverage of the target volume and sparing of critical organs for prostate cancer patients treated with intensity modulated radiotherapy (IMRT) and determination of planning margins by original approach of detailed daily dose volume histogram (DVH) and patient's position correction analysis. Sixty-two patients divided in two groups (clinical target volume (CTV) -> planning target volume (PTV) margin 10 and 7 mm) were treated with IMRT using implanted fiducial markers. Each patient's treatment fraction was recalculated as it would have been treated without fiducial-guided positioning. For both plans (IGRT and non-IGRT), equivalent uniform doses (EUD), maximal and minimal doses for target volumes, normal tissue complication probability (NTCP), maximum and mean doses for organs at risk and the whole DVH differences were assessed. In the group with 10 mm margins, the only significant difference was worse rectal NTCP by 4.5%, but the CTV dose coverage remained at the same level. Recalculated plans with 7 mm margin could not achieve the prescribed target volume coverage, and the EUD decreased by 3.7 and 0.6 Gy for PTV and CTV, respectively. Desired CTV -> PTV margin for non-IGRT plans should be no lower than 12 mm to guarantee 95% instances when delivered dose to CTV maintain as planned, for IGRT plans decrease this requirement to 2mm. Prostate IMRT strategies involving margin reduction below 7 mm require image-guidance to maintain the planned dose coverage. Using fiducial-based image-guidance and large margins seems to be superfluous.
dcterms:title
Quantitative Evaluation of the Benefit of Fiducial Image-Guidance for Prostate Cancer Intensity Modulated Radiation Therapy using Daily Dose Volume Histogram Analysis Quantitative Evaluation of the Benefit of Fiducial Image-Guidance for Prostate Cancer Intensity Modulated Radiation Therapy using Daily Dose Volume Histogram Analysis
skos:prefLabel
Quantitative Evaluation of the Benefit of Fiducial Image-Guidance for Prostate Cancer Intensity Modulated Radiation Therapy using Daily Dose Volume Histogram Analysis Quantitative Evaluation of the Benefit of Fiducial Image-Guidance for Prostate Cancer Intensity Modulated Radiation Therapy using Daily Dose Volume Histogram Analysis
skos:notation
RIV/00216208:11150/14:10271899!RIV15-MSM-11150___
n4:aktivita
n10:S n10:V
n4:aktivity
S, V
n4:cisloPeriodika
1
n4:dodaniDat
n14:2015
n4:domaciTvurceVysledku
n6:2909448 n6:4388739 n6:6210554
n4:druhVysledku
n7:J
n4:duvernostUdaju
n5:S
n4:entitaPredkladatele
n17:predkladatel
n4:idSjednocenehoVysledku
41093
n4:idVysledku
RIV/00216208:11150/14:10271899
n4:jazykVysledku
n12:eng
n4:klicovaSlova
Safety margin; Dose volume histogram; Fiducial markers; Prostate radiotherapy
n4:klicoveSlovo
n8:Prostate%20radiotherapy n8:Fiducial%20markers n8:Safety%20margin n8:Dose%20volume%20histogram
n4:kodStatuVydavatele
US - Spojené státy americké
n4:kontrolniKodProRIV
[4A48ED5DA70E]
n4:nazevZdroje
Technology in Cancer Research and Treatment
n4:obor
n19:FD
n4:pocetDomacichTvurcuVysledku
3
n4:pocetTvurcuVysledku
5
n4:rokUplatneniVysledku
n14:2014
n4:svazekPeriodika
13
n4:tvurceVysledku
Kašaová, Linda Paluska, Petr Jansa, Jan Sirák, Igor Petera, Jiří
n4:wos
000330143900006
s:issn
1533-0346
s:numberOfPages
9
n18:doi
10.7785/tcrt.2012.500352
n15:organizacniJednotka
11150